| Issue |
Section |
Title |
File |
| Vol 22, No 4 (2020) |
CLINICAL ONCOLOGY |
The virtual forum on the diagnosis and treatment of PIK3CA-mutated metastatic breast cancer. October 16th, 2020. Event review |
(Rus)
|
| Vol 22, No 4 (2020) |
CLINICAL ONCOLOGY |
Improving early breast cancer treatment: the role of granulocyte colony-stimulating factor |
(Rus)
|
| Vol 23, No 1 (2021) |
CLINICAL ONCOLOGY |
Breast cancer |
(Rus)
|
| Vol 23, No 1 (2021) |
CLINICAL ONCOLOGY |
Antiangiogenic therapy for breast cancer with triple negative phenotype |
(Rus)
|
| Vol 24, No 1 (2022) |
CLINICAL ONCOLOGY |
NGAL and KIM-1 – early urinary biomarkers of nephrotoxicity mediated by cisplatin: Observational study |
(Rus)
|
| Vol 23, No 4 (2021) |
CLINICAL ONCOLOGY |
The consensus on the prevention and correction of rash in patients with HR+ HER2- metastatic breast cancer treated with alpelisib |
(Rus)
|
| Vol 24, No 3 (2022) |
CLINICAL ONCOLOGY |
Antitumor response and quality of life: is there a need to sacrifice? Clinical observation: long-term and safe control of the disease using a combination of ribociclib with letrozole. Case report |
(Rus)
|
| Vol 25, No 3 (2023) |
CLINICAL ONCOLOGY |
Resolution of the advisory board on the topic: “The place of entrectinib in the treatment of adult patients with NTRK-fusion positive solid tumors” |
(Rus)
|
| Vol 24, No 4 (2022) |
CLINICAL ONCOLOGY |
Real-world efficacy of the first line therapy with prolgolimab in patients with metastatic melanoma: interim results of the FORA (FOrteca Real practice Assessment) observational study |
(Rus)
|
| Vol 25, No 1 (2023) |
CLINICAL ONCOLOGY |
The effect of CDK4/6 inhibitors on the overall survival in patients with advanced HR+/HER2- BC in the entire population and in special clinical subgroups of unfavorable prognosis: A review |
(Rus)
|
| Vol 25, No 2 (2023) |
CLINICAL ONCOLOGY |
The role of neoadjuvant chemotherapy in patients with primary resectable pancreatic cancer: A retrospective cohort study |
(Rus)
|
| Vol 25, No 4 (2023) |
CLINICAL ONCOLOGY |
How a significant increase in survival in pancreatic cancer is achieved. The role of nutritional status and supportive care: A review |
(Rus)
|
| Vol 26, No 2 (2024) |
Articles |
Effect of internal subtype on the efficacy of CDK4/6 inhibitor therapy in advanced HR+/HER2breast cancer: A review |
(Rus)
|
| Vol 26, No 1 (2024) |
Articles |
Final data on the efficacy of the FORA study (FOrteca Real practice Assessment): a multicenter prospective observational study on the real-world efficacy of prolgolimab in patients with metastatic melanoma in Russia |
(Rus)
|
| Vol 26, No 1 (2024) |
Articles |
Safety and efficacy of ribociclib in combination with letrozole in an extended population of patients with HR+/HER2- advanced breast cancer: analysis of data from a subgroup of patients from Russia in the phase lllb CompLEEment-1 study |
(Rus)
|
| Vol 27, No 1 (2025) |
Articles |
Evolution of anti-HER2 therapy in advanced HER2+ breast cancer or “why is trastuzumab still a key player?”. A review |
(Rus)
|
| Vol 26, No 3 (2024) |
Articles |
Comparison of the efficacy of neoadjuvant chemotherapy with FLOT regimen and adjuvant chemotherapy with XELOX/FOLFOX regimen in patients with locally advanced gastric cancer: A retrospective study |
(Rus)
|
| Vol 26, No 3 (2024) |
Articles |
The combination of lenvatinib and pembrolizumab in the treatment of patients with metastatic kidney cancer and factors of poor prognosis: experience of clinics in Moscow: A prospective observational study |
(Rus)
|
| Vol 26, No 3 (2024) |
Articles |
Role of enzyme replacement therapy for exocrine and nutritional insufficiency in patients with malignancies: A review |
(Rus)
|
| Vol 26, No 3 (2024) |
Articles |
Retrospective analysis of the safety and efficacy of Pembroria® during non-medical switching from the original drug Keytruda® in patients with advanced malignancies of various localizations in real clinical practice |
(Rus)
|
| Vol 26, No 4 (2024) |
Articles |
First results of a multicenter, non-randomized, prospective phase II study of the efficacy and safety of induction therapy with pembrolizumab, cisplatin, and 5-fluorouracil in patients with unresectable squamous cell carcinoma of the oropharynx, hypopharynx and larynx |
(Rus)
|
